Franklin Berger

Franklin Berger

Directeur/Bestuurslid bij ATEA PHARMACEUTICALS, INC.

Vermogen: 9 M $ op 30-09-2026

76 jaar
Health Technology
Finance
Consumer Services

Profiel

Mr. Franklin M.
Berger
, CFA MBA, is an Independent Director at Retension Pharmaceuticals, Inc., a Lead Independent Director at Atea Pharmaceuticals, Inc., a Senior Advisor at Qiming US Ventures Management, LLC and a Managing Director at FMB Research.
He is on the Board of Directors at Retension Pharmaceuticals, Inc., Satellos Bioscience, Inc., Atea Pharmaceuticals, Inc. and Walking Fish Therapeutics, Inc. Mr. Berger was previously employed as a Lead Independent Director by Rain Oncology, Inc., a Chairman by Proteostasis Therapeutics, Inc., an Independent Director by ESSA Pharma, Inc., an Independent Director by Atreca, Inc., an Independent Director by Tocagen, Inc., an Independent Director by Immune Design Corp., an Independent Director by BioTime, Inc., an Independent Director by Five Prime Therapeutics, Inc., an Independent Director by BELLUS Health, Inc., a Lead Independent Director by Thallion Pharmaceuticals, Inc., a Senior Manager-Portfolio by NEMO Fund, Inc., a Senior Manager-Investment by Sectoral Asset Management, Inc., an Independent Director by Seattle Genetics, Inc., a Managing Director-Equity Research by JPMorgan Securities, Inc., a Managing Director-Equity Research by Salomon Smith Barney, Inc., a Director-Equity Research by Smith Barney Asset Management, a Managing Director-Equity Research by Josephthal, Lyon & Ross, Inc., and an Advisor by Brookline Capital Acquisition Corp.
He also served on the board at Applied Therapeutics, Inc., Kezar Life Sciences, Inc., Emisphere Technologies, Inc., Isotechnika Pharma, Inc., Isotechnika, Inc., VaxGen, Inc., Alzheon, Inc., Asterias Biotherapeutics, Inc., Aurinia Pharmaceuticals, Inc., Caprion Proteomics, Inc., CellCarta Biosciences, Inc., Episcopal Relief & Development Corp., HealthShares, Inc., iTherX Pharmaceuticals, Inc., The Genetics Co., Inc. and ViroChem Pharma, Inc.

Bekende belangen in openbare bedrijven

OndernemingDatumAantal aandelenTotale waardeWaarderingsdatum
18-08-2026 690.067 ( 3,25% ) 6 M $ 30-09-2026
18-06-2026 536.097 ( 0,67% ) 3 M $ 30-09-2026
0,27%
13-10-2026 22.517 ( 0,27% ) 237 104 $ 30-09-2026

Actieve functies van Franklin Berger

BedrijvenFunctieBegin
ATEA PHARMACEUTICALS, INC. Directeur/Bestuurslid 01-09-2019
SATELLOS BIOSCIENCE INC. Directeur/Bestuurslid 29-06-2023
Algemeen Directeur 01-06-2005
Consultant / Adviseur 01-01-2019
Directeur/Bestuurslid -

Eerdere bekende functies van Franklin Berger

BedrijvenFunctieEinde
KEZAR LIFE SCIENCES, INC. Directeur/Bestuurslid 11-05-2026
ESSA PHARMA INC. Directeur/Bestuurslid 09-10-2025
ATRECA, INC. Directeur/Bestuurslid 13-05-2024
RAIN ONCOLOGY INC. Directeur/Bestuurslid 25-01-2024
░░░░░░ ░░░░░░ ░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
Ervaring van Franklin Berger in detail bekijken

Opleiding van Franklin Berger

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Connecties

65

Eerstegraads connecties

41

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Verwante bedrijven

Bedrijven in privébezit41

Health Technology

Health Technology

Distribution Services

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Finance

Finance

Consumer Services

Health Technology

Miscellaneous

Health Technology

Commercial Services

Health Technology

Health Services

Health Technology

Finance

Health Technology

Commercial Services

NEMO Fund, Inc.

Health Technology

Health Technology

Consumer Services

Health Technology

Miscellaneous

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Finance

Health Technology

  1. Beurs
  2. Insiders
  3. Franklin Berger